DCI Stock Analysis: Donaldson | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 10.007m USD | 12M Return: 10.6% | US2576511099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 57.8M
EPS Trend: 98.0%
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Donaldson Company, Inc. is a global manufacturer of filtration systems and replacement parts, organized into three segments: Mobile Solutions, Industrial Solutions, and Life Sciences. Its products serve a wide range of end markets, including construction, mining, agriculture, transportation, aerospace and defense, food and beverage processing, and semiconductor manufacturing. The company was founded in 1915 and is headquartered in Bloomington, Minnesota.
The Mobile Solutions segment supplies air, fuel, lube, and hydraulic filtration to OEMs and dealer networks in heavy-duty equipment and transportation markets. The Industrial Solutions segment provides dust collection, compressed air purification, and aerospace and defense filtration products to distributors, OEMs, and end-users. The Life Sciences segment delivers micro-environment gas and liquid filtration, bioprocessing equipment and consumables, and specialized filtration for semiconductors, hard disk drives, and battery systems.
Donaldson operates within the industrial machinery and supplies sub-industry, where filtration demand tends to be supported by recurring replacement-parts revenue and tightening emissions and air quality regulations worldwide. Its diversified end-market exposure across mobile equipment, industrial process filtration, and life sciences helps balance cyclical and growth-oriented demand cycles.
- Global emissions tightening drives filtration replacement demand
- Heavy equipment OEM cycle pressures Mobile Solutions revenue
- Life Sciences scales on bioprocessing and semiconductor filtration
| Net Income: 453.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.67 > 1.0 |
| NWC/Revenue: 22.28% < 20% (prev 19.09%; Δ 3.19% < -1%) |
| CFO/TA 0.12 > 3% & CFO 493.7m > Net Income 453.8m |
| Net Debt (1.09b) to EBITDA (727.8m): 1.50 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (117.9m) vs 12m ago -0.17% < -2% |
| Gross Margin: 34.64% > 18% (prev 34.85%; Δ -0.21% > 0.5%) |
| Asset Turnover: 111.6% > 50% (prev 124.0%; Δ -12.38% > 0%) |
| Interest Coverage Ratio: 17.27 > 6 (EBIT TTM 621.8m / Interest Expense TTM 36.0m) |
| A: 0.22 (Total Current Assets 1.67b - Total Current Liabilities 804.1m) / Total Assets 3.99b |
| B: 0.72 (Retained Earnings 2.87b / Total Assets 3.99b) |
| C: 0.18 (EBIT TTM 621.8m / Avg Total Assets 3.48b) |
| D: 0.79 (Book Value of Equity 1.76b / Total Liabilities 2.22b) |
| Altman-Z'' = 5.80 = AAA |
| DSRI: 1.09 (Receivables 758.1m/662.2m, Revenue 3.89b/3.69b) |
| GMI: 1.01 (GM 34.85% / 34.64%) |
| AQI: 1.55 (AQ_t 0.42 / AQ_t-1 0.27) |
| SGI: 1.05 (Revenue 3.89b / 3.69b) |
| TATA: -0.01 (NI 453.8m - CFO 493.7m) / TA 3.99b) |
| Beneish M = -2.58 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 87.41 with a total of 483,050 shares traded. Over the past week, the price has changed by +1.12%, over one month by -6.27%, over three months by -1.58% and over the past year by +10.63%.
Current recommended Stop Loss: 85.00 (which is 2.8% or 1.3 ATR below the current price).
Donaldson has received a consensus analysts rating of 3.38. Therefore, it is recommended to hold DCI.
- StrongBuy: 2
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 99.6 | 13.9% |
P/E Trailing = 22.452
P/E Forward = 19.8413
P/S = 2.6228
P/B = 5.6786
P/EG = 1.5861
Revenue TTM = 3.89b USD
EBIT TTM = 621.8m USD
EBITDA TTM = 727.8m USD
Long Term Debt = 591.6m USD (from longTermDebt, two quarters ago)
Short Term Debt = 44.8m USD (from shortTermDebt, last quarter)
Debt = 1.34b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.1m
Net Debt = 1.09b USD (calculated: Debt 1.34b - CCE 250.4m)
Enterprise Value = 11.1b USD (10.0b + Debt 1.34b - CCE 250.4m)
Interest Coverage Ratio = 17.27 (Ebit TTM 621.8m / Interest Expense TTM 36.0m)
EV/FCF = 26.04x (Enterprise Value 11.1b / FCF TTM 426.3m)
FCF Yield = 3.84% (FCF TTM 426.3m / Enterprise Value 11.1b)
FCF Margin = 10.97% (FCF TTM 426.3m / Revenue TTM 3.89b)
Net Margin = 11.68% (Net Income TTM 453.8m / Revenue TTM 3.89b)
Gross Margin = 34.64% ((Revenue TTM 3.89b - Cost of Revenue TTM 2.54b) / Revenue TTM)
Gross Margin QoQ = 36.26% (prev 33.50%)
Tobins Q-Ratio = 2.78 (Enterprise Value 11.1b / Total Assets 3.99b)
Interest Expense / Debt = 2.68% (Interest Expense 36.0m / Debt 1.34b)
Taxrate = 22.53% (132.0m / 585.8m)
NOPAT = 481.7m (EBIT 621.8m * (1 - 22.53%))
Current Ratio = 2.08 (Total Current Assets 1.67b / Total Current Liabilities 804.1m)
Debt / Equity = 0.76 (Debt 1.34b / totalStockholderEquity, last quarter 1.76b)
Debt / EBITDA = 1.50 (Net Debt 1.09b / EBITDA 727.8m)
Debt / FCF = 2.56 (Net Debt 1.09b / FCF TTM 426.3m)
Total Stockholder Equity = 1.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.03% (Net Income 453.8m / Total Assets 3.99b)
RoE = 27.71% (Net Income TTM 453.8m / Total Stockholder Equity 1.64b)
RoCE = 27.89% (EBIT 621.8m / Capital Employed (Equity 1.64b + L.T.Debt 591.6m))
RoIC = 15.88% (NOPAT 481.7m / Invested Capital 3.03b)
WACC = 8.05% (E(10.0b)/V(11.3b) * Re(8.85%) + D(1.34b)/V(11.3b) * Rd(2.68%) * (1-Tc(0.23)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.47 | Cagr: -1.83%
[DCF] Terminal Value 77.97% ; FCFF base≈391.1m ; Y1≈448.3m ; Y5≈659.8m
[DCF] Fair Price = 76.24 (EV 9.93b - Net Debt 1.09b = Equity 8.84b / Shares 115.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.00 | EPS CAGR: 9.79% | SUE: 0.80 | # QB: 0
Revenue Correlation: 98.42 | Revenue CAGR: 4.07% | SUE: 0.42 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.97 | Chg30d=-4.82% | Revisions=-50% | Analysts=5
EPS next Quarter (2027-01-31): EPS=0.90 | Chg30d=-5.80% | Revisions=-50% | Analysts=5
EPS current Year (2027-07-31): EPS=4.33 | Chg30d=-0.89% | Revisions=-17% | GrowthEPS=+8.9% | GrowthRev=+7.5%
EPS next Year (2028-07-31): EPS=4.85 | Chg30d=-0.33% | Revisions=+17% | GrowthEPS=+12.0% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -40% (up=3, down=9)